
Practiced intensive care cardiology, outpatient cardiology and did clinical research for > 30 years. Founded the Duke Clinical Research Institute. Served as 23rd and 26th FDA Commissioner. Worked at Alphabet from 2017-22.
| Platform | Pricing | Only free issues | Publishes | Weekly | |
|---|---|---|---|---|---|
| Issues | 37 | Founded | a year ago | Last Issue | 2 months ago |
| Active | |||||

Hal Gatewood/Unsplash
This is the third in a three-part series on the FDA’s Form 483, a tool that the agency uses to notify firms that an investigator has found evidence for lack of adherence to quality regulations related to the manufactu...
Adrien/Unsplash
In Part 1 of this series on the FDA’s use of a regulatory instrument known as Form 483, I put forward my view of the form and how I hope it will be used to improve quality across the board rather than as a single summary es...
US Food and Drug Administration
In this first of three related posts, I’ll be diving into a topic that some may find esoteric, but which I believe it has a significant effect on the efficiency and effectiveness of manufacturing and clinica...
Abdulai Sayni/Unsplash
This is the fourth installment in a series on congenital heart disease (CHD). I’ve offered my views on the opportunity to improve the knowledge base, clinical care, and outcomes for both children and adults with CHD....
Kelly Sikkema/Unsplash
The first two installments in this series discussed the opportunity to better organize care for congenital heart disease (CHD) and the importance of creating and sustaining centers for high-quality care, such as a co...
Subscribers, engagement, traffic and sponsorship for Califf's Commentary.
| Subscribers | Engagement | 71 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
The writers behind this newsletter.
Practiced intensive care cardiology, outpatient cardiology and did clinical research for > 30 years. Founded the Duke Clinical Research Institute. Served as 23rd and 26th FDA Commissioner. Worked at Alphabet from 2017-22.
You can find recent issues that have been published by Califf's Commentary on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to Califf's Commentary, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch Califf's Commentary as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Califf's Commentary using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like Califf's Commentary. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.